NL-OMON23606尚未招募不适用
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk
eiden University Medical Center (LUMC)0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with AML or high risk MDS (IPSS-R ¡Ý 4.5)
- •2. > 65 years
排除标准
- •1. Previous treatment with decitabine, azacitidine or intensive chemotherapy for this MDS/AML (treatment with chemotherapy for previous other diseases is acceptable)
- •2. Acute promyelocytic leukemia
研究者
相似试验
进行中（未招募）
不适用
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality riskAcute myeloid leukemia and high risk myelodysplasiaEUCTR2015-004896-60-NLeiden University Medical Center
已完成
2 期
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality riskmyelodysplasia10024324acute leukemiaNL-OMON42455eids Universitair Medisch Centrum19
已完成
不适用
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.Acute Myeloid LeukemiaNCT03350152Hospices Civils de Lyon302
进行中（未招募）
3 期
"InDACtion" vs "3+7" Induction in AMLAcute Myeloid Leukemia (AML)NCT02172872European Organisation for Research and Treatment of Cancer - EORTC606
Unknown
1 期
Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT01488344University Hospital Muenster140